Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

NCT04461795 PHASE4 COMPLETED Results posted

This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.

Details

Lead sponsor	David True
Phase	PHASE4
Status	COMPLETED
Enrolment	40
Start date	Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jan 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Migraine

Interventions

• Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]

Countries

United States